-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.50131.09% Upside
Calidi Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Robert W. Baird in the past 90 days.